Aardvark Therapeutics Faces Legal Action with Upcoming Plaintiff Deadline in 2026
In recent developments, SueWallSt has issued a crucial reminder to investors involved with Aardvark Therapeutics, Inc. (NASDAQ: AARD). A securities class action lawsuit has been filed, highlighting significant concerns regarding the company's disclosures. The critical lead plaintiff deadline is set for October 13, 2026, impacting shareholders who purchased or acquired securities from February 13, 2025, to May 14, 2026, inclusive of those participating in the February 2025 initial public offering.
The lawsuit alleges that Aardvark Therapeutics made misleading claims about their drug ARD-101, particularly regarding its safety profile and clinical risk disclosures. During its communications, the company described ARD-101 as "99% restricted to the gut" and claimed it posed no serious adverse events. However, the lawsuit posits that these claims did not adequately disclose specific risks, particularly relating to cardiac safety issues that led to an FDA clinical hold. The company’s SEC filings, while emphasizing limited systemic absorption to reduce toxicity, failed to address the serious cardiac observations noted during routine safety monitoring.
Aardvark launched its shares at $16.00 each, raising approximately $87.6 million in net proceeds. Yet, by May 15, 2026, the stock plummeted to $4.57—marking a staggering decline of around 71.4%. The drop in share value came in the wake of announcements concerning the company’s Phase 3 HERO trial, which faced a voluntary pause due to unforeseen cardiac concerns. Following this announcement, shares fell sharply, demonstrating the significant financial repercussions investors faced as disclosures became less favorable.
The core argument of the lawsuit highlights several critical gaps in the company’s disclosures:
1. Generalized Safety Statements: While the company stated that ARD-101 exhibited limited systemic absorption and no serious adverse effects, the lawsuit argues that it failed to highlight known cardiac safety risks.
2. Misleading Tolerability Claims: Data presented by Aardvark regarding the pharmacokinetics of ARD-101 for gut restriction was reportedly generalized and misleading, failing to reflect concerns related to safety at higher therapeutic doses in clinical trials.
3. Regulatory Delays: Guidance regarding the timeline for topline HERO data was omitted, creating market volatility when the data was delayed.
The situation escalated in early 2026 when Aardvark announced a voluntary pause in its clinical studies due to reports of reversible cardiac issues linked to ARD-101. Following this announcement, the company expected to see a decline in stock value, which indeed occurred. By May 14, 2026, news about an FDA clinical hold sent shares tumbling further, reflecting investor panic over the regulatory and reputational status of the company.
Investors affected by these developments are encouraged to connect with legal counsel to determine their eligibility for recovery. Joseph E. Levi, Esq. from Levi Korsinsky LLP, the law firm powering SueWallSt, is available for consultations at no upfront cost. The firm has a reputation for successfully handling complex securities litigation and offers extensive resources for aggrieved shareholders.
The majority of affected investors are unlikely to have to appear in court, as securities class actions typically resolve with claims submitted post-settlement. Ultimately, Aardvark Therapeutics faces serious scrutiny, and shareholders should be prepared to take action by the upcoming lead plaintiff deadline. For those interested in learning more about their rights and potential recovery, contact details are available through Levi Korsinsky, LLP.
Background of the Case
The lawsuit alleges that Aardvark Therapeutics made misleading claims about their drug ARD-101, particularly regarding its safety profile and clinical risk disclosures. During its communications, the company described ARD-101 as "99% restricted to the gut" and claimed it posed no serious adverse events. However, the lawsuit posits that these claims did not adequately disclose specific risks, particularly relating to cardiac safety issues that led to an FDA clinical hold. The company’s SEC filings, while emphasizing limited systemic absorption to reduce toxicity, failed to address the serious cardiac observations noted during routine safety monitoring.
Significant Financial Impact
Aardvark launched its shares at $16.00 each, raising approximately $87.6 million in net proceeds. Yet, by May 15, 2026, the stock plummeted to $4.57—marking a staggering decline of around 71.4%. The drop in share value came in the wake of announcements concerning the company’s Phase 3 HERO trial, which faced a voluntary pause due to unforeseen cardiac concerns. Following this announcement, shares fell sharply, demonstrating the significant financial repercussions investors faced as disclosures became less favorable.
Details of Allegations
The core argument of the lawsuit highlights several critical gaps in the company’s disclosures:
1. Generalized Safety Statements: While the company stated that ARD-101 exhibited limited systemic absorption and no serious adverse effects, the lawsuit argues that it failed to highlight known cardiac safety risks.
2. Misleading Tolerability Claims: Data presented by Aardvark regarding the pharmacokinetics of ARD-101 for gut restriction was reportedly generalized and misleading, failing to reflect concerns related to safety at higher therapeutic doses in clinical trials.
3. Regulatory Delays: Guidance regarding the timeline for topline HERO data was omitted, creating market volatility when the data was delayed.
Regulatory Developments
The situation escalated in early 2026 when Aardvark announced a voluntary pause in its clinical studies due to reports of reversible cardiac issues linked to ARD-101. Following this announcement, the company expected to see a decline in stock value, which indeed occurred. By May 14, 2026, news about an FDA clinical hold sent shares tumbling further, reflecting investor panic over the regulatory and reputational status of the company.
Moving Forward
Investors affected by these developments are encouraged to connect with legal counsel to determine their eligibility for recovery. Joseph E. Levi, Esq. from Levi Korsinsky LLP, the law firm powering SueWallSt, is available for consultations at no upfront cost. The firm has a reputation for successfully handling complex securities litigation and offers extensive resources for aggrieved shareholders.
The majority of affected investors are unlikely to have to appear in court, as securities class actions typically resolve with claims submitted post-settlement. Ultimately, Aardvark Therapeutics faces serious scrutiny, and shareholders should be prepared to take action by the upcoming lead plaintiff deadline. For those interested in learning more about their rights and potential recovery, contact details are available through Levi Korsinsky, LLP.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.